Abstract
Background. Our aim was to evaluate the quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. We also conducted an analysis of all patients who underwent CRS and HIPEC for pseudomyxoma peritonei from 1997 to 2012. Methods. We contacted 87 patients using the FACT C (version 4) quality of life questionnaire, and FACIT-TS-G (version 1) was also used. Results. A total of 63 patients (response rate 72%) were available for quality of life interview and analysis. The median time from surgery to questionnaire evaluation was 31 months (range 6–161 months). 62% were females with an average age of 54 years. 22% of the patients had over one cytoreductive surgical procedure. We analysed our patients postoperatively based on physical, functional, social, and emotional well being who reported favourable outcomes in all sections. Patients who had a single procedure had a significantly higher score (P = 0.016) in the additional concerns section of the questionnaire. The patients who had a single procedure had better gastrointestinal digestion in terms of bowel control, appetite, and food digestion and also body appearance scoring. Conclusions. 79% of the patients stated that they would undergo further cytoreductive surgery and that redo procedures do not result in a significantly worse quality of life.
Highlights
As a result of pioneering work by Sugarbaker, cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have become the mainstay of treatment for pseudomyxoma peritonei (PMP) [1].Appendiceal neoplasms are uncommon making up 1% of colorectal malignancies [2]
CRS and HIPEC were carried out as per the Sugarbaker technique [13] with eighty percent of patients who responded to the questionnaire receiving EPIC in our high dependency or intensive care unit
There is no significant difference in quality of life scores between patients who had a single versus redo procedure
Summary
As a result of pioneering work by Sugarbaker, cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have become the mainstay of treatment for pseudomyxoma peritonei (PMP) [1].Appendiceal neoplasms are uncommon making up 1% of colorectal malignancies [2]. As a result of pioneering work by Sugarbaker, cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have become the mainstay of treatment for pseudomyxoma peritonei (PMP) [1]. Most cases of PMP result from rupture of a low grade appendiceal tumour with mucin accumulating in the abdominal cavity due to its production by epithelial cells. Our aim was to evaluate the quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Patients who had a single procedure had a significantly higher score (P = 0.016) in the additional concerns section of the questionnaire. 79% of the patients stated that they would undergo further cytoreductive surgery and that redo procedures do not result in a significantly worse quality of life Conclusions. 79% of the patients stated that they would undergo further cytoreductive surgery and that redo procedures do not result in a significantly worse quality of life
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
